ClinicalTrials.gg
CompletedNCT06790121Updated Apr 21, 2026

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of Lunsekimig and Placebo in Dermatitis Atopic, sponsored by Sanofi. Completed at 52 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.

Enrollment
12th of 28
150 · median 112
Started
2025
with 2 others
Phase 2
8 of 43
none open now
Registered
38th of 43
by date

Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 in phase 2, and was the 38th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dermatitis, Atopic by Sanofi, or all of them as a file.
02

Study summary

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD).

This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate response to topical treatments or for whom topical therapies are not advised. The study consists of 6 arms: 3 parallel dosing regimens and matching placebo arms. Additionally, participants have the option of engaging in a dense pharmacokinetic/pharmodynamic (PK/PD) sampling subgroup.

The study duration will be up to approximately 36 weeks, including up to 4 weeks of screening, 24 weeks of treatment period and an 8-week safety follow-up period.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 to 80 years of age, inclusive, at the time of signing the .
  • Diagnosis of Atopic Dermatitis (AD) as defined by the American Academy of Dermatology (AAD) clinical guidelines (2023) for 1 year or longer at baseline (Day 1)
  • Documented history within 6 months prior to Screening Visit, of either inadequate response or inadvisability of topical treatments
  • Eczema Area and Severity Index (EASI) score of 16 or higher (range, 0 to 72) at baseline (Day 1)
  • Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score of 3 or 4 at baseline visit (Day 1) (on the 0 to 4 vIGA-AD scale, a vIGA-AD score of 3 and 4 represents moderate and severe, respectively).
  • AD involvement of 10% or more of Body Surface Are (BSA) at baseline (Day 1)
  • Weekly average of daily Peak Pruritis-Numerical Rating (PP-NRS) score of ≥4 at baseline (Day 1)
  • Must have applied a stable dose of topical bland emollient (simple moisturizer, no additives [eg, urea]) at least once daily for a minimum of 5 out of 7 consecutive days before baseline (Day 1).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Skin comorbidity that would adversely affect the ability to undertake AD assessments (eg, psoriasis, tinea corporis, and lupus erythematosus) according to the Investigator's judgment.
  • Known history of, or suspected, significant current

NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Lunsekimig arm A

    Participants will receive subcutaneous injection of lunsekimig dosing regimen A.

    Drug: Lunsekimig

  • Placebo comparator
    Placebo arm B

    Participants will receive subcutaneous injection of matching placebo.

    Drug: Placebo

  • Experimental
    Lunsekimig arm C

    Participants will receive subcutaneous injection of lunsekimig dosing regimen C.

    Drug: Lunsekimig

  • Placebo comparator
    Placebo arm D

    Participants will receive subcutaneous injection of matching placebo.

    Drug: Placebo

  • Experimental
    Lunsekimig arm E

    Participants will receive subcutaneous injection of lunsekimig dosing regimen E.

    Drug: Lunsekimig

  • Placebo comparator
    Placebo arm F

    Participants will receive subcutaneous injection of matching placebo.

    Drug: Placebo

Interventions

  • Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

    Also known as: SAR443765

  • DrugPlacebo

    Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24

    Eczema Area and Severity index is an Investigator-assessed validated tool used to measure the extent (area) and severity of atopic dermatitis (AD). Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: From Baseline throughout the study, up to Week 24

Secondary outcomes

  1. Proportion of participants achieving EASI-75 at Week 24

    EASI 75 is defined by reduction of EASI score by ≥75% from baseline

    Time frame: From Baseline throughout the study, up to Week 24

  2. Proportion of participants with a Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score of 0 (clear) or 1 (almost clear) and a reduction from Baseline of ≥2 points at Week 24

    The Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score is a 5-point scale used to determine severity of AD and clinical response to treatment, ranging from 0 (clear) to 4 (severe).

    Time frame: From Baseline throughout the study, up to Week 24

  3. Proportion of participants with reduction (improvement) of ≥4 in the weekly average of daily Peak Pruritis-Numerical Rating Scale (PP-NRS) score from Baseline to Week 24

    The Peak Pruritis-Numerical Rating Scale (PP-NRS) is a validated single-item patient-reported outcome (PRO) to assess worst itch intensity on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: From Baseline throughout the study, up to Week 24

  4. Absolute change from Baseline in EASI score at Week 24

    Eczema Area and Severity index is an Investigator-assessed validated tool used to measure the extent (area) and severity of atopic dermatitis (AD). Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: From Baseline throughout the study, up to Week 24

  5. Percent change from Baseline in EASI score throughout the study

    Eczema Area and Severity index is an Investigator-assessed validated tool used to measure the extent (area) and severity of atopic dermatitis (AD). Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: From Baseline throughout the study, up to Week 24

  6. Proportion of participants with a vIGA-AD score of 0 (clear) or 1 (almost clear) at Week 24

    The Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score is a 5-point scale used to determine severity of AD and clinical response to treatment, ranging from 0 (clear) to 4 (severe).

    Time frame: From Baseline throughout the study, up to Week 24

  7. Proportion of participants with a response of vIGA-AD 0 or 1 and a reduction from Baseline of ≥2 points throughout the study

    The Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score is a 5-point scale used to determine severity of AD and clinical response to treatment, ranging from 0 (clear) to 4 (severe).

    Time frame: From Baseline throughout the study, up to Week 24

  8. Percent change in the weekly average of daily PPNRS scores from Baseline to Week 24

    The Peak Pruritis-Numerical Rating Scale (PP-NRS) is a validated single-item patient-reported outcome (PRO) to assess worst itch intensity on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: From Baseline throughout tje study, up to Week 24

  9. Percent change in the weekly average of daily sleep disturbance NRS score from Baseline to Week 24

    The Sleep Disturbance-Numerical Rating Scale (SD-NRS) is a validated single item 0-10 numerical rating scale assessing sleep disturbance associated with AD, with 0 being 'no sleep loss related to the symptoms of AD' and 10 being 'I did not sleep at all' due to the symptoms of AD.

    Time frame: From Baseline throughout the study, up to Week 24

  10. Percent change in the weekly average of daily skin pain NRS score from Baseline to Week 24

    The Skin Pain-NRS is a whole number scale ranging from 0 to 10 with a 24-hour recall period, with 0 = no pain and 10 = worst possible pain imaginable. The threshold for determining clinically meaningful change is ≥ 4-point change in the weekly average SP-NRS.

    Time frame: From Baseline throughout the study, up to Week 24

  11. Change in percent Body Surface Area (BSA) affected by Atopic Dermatitis from Baseline to Week 24.

    The BSA affected by AD will be assessed in 4 body regions: head/neck, trunk (including the genitals), upper extremities, and lower extremities (including the buttocks). Each body region should be evaluated from 0 to 100%. The percentage of the affected area will be multiplied by the proportion of that body region to the whole body.

    Time frame: From Baseline throughout the study, up to Week 24

  12. Proportion of participants achieving EASI-50 at Week 24

    EASI-50 is defined by reduction of EASI score by ≥50% from baseline.

    Time frame: From Baseline throughout the study, up to Week 24

  13. Proportion of participants achieving EASI-90 at Week 24

    EASI-90 is defined by reduction of EASI score by ≥90% from baseline.

    Time frame: From Baseline throughout the study, up to Week 24

  14. Proportion of participants with improvement (reduction) of ≥4 points in the weekly average of daily PP NRS scores from Baseline throughout the study

    The Peak Pruritis-Numerical Rating Scale (PP-NRS) is a validated single-item patient-reported outcome (PRO) to assess worst itch intensity on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: From Baseline throughout the study, up to Week 24

  15. Proportion of participants with improvement (reduction) of ≥4 points in the weekly average of daily SD-NRS scores from Baseline to Week 24, in participants with a baseline weekly average of daily SD-NRS scores of ≥4 points

    The Sleep Disturbance-Numerical Rating Scale (SD-NRS) is a validated single item 0-10 numerical rating scale assessing sleep disturbance associated with AD, with 0 being 'no sleep loss related to the symptoms of AD' and 10 being 'I did not sleep at all' due to the symptoms of AD.

    Time frame: From Baseline throughout the study, up to Week 24

  16. Proportion of participants with improvement (reduction) of ≥4 points in the weekly average of daily Skin Pain NRS scores from Baseline to Week 24, in participants with a baseline weekly average of daily Skin Pain NRS scores of ≥4 points

    The Skin Pain--Numerical Rating Scale (SP-NRS) is a whole number scale ranging from 0 to 10 with a 24-hour recall period, with 0 = no pain and 10 = worst possible pain imaginable. The threshold for determining clinically meaningful change is ≥ 4-point change in the weekly average SP-NRS.

    Time frame: From Baseline throughout the study, up to Week 24

  17. Percent change in Scoring of Atopic Dermatitis (SCORAD) Index from Baseline to Week 24

    The Scoring of Atopic Dermatitis (SCORAD) Index is a validated clinical tool that was developed to standardize the evaluation of the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: From Baseline throughout the study, up to Week 24

  18. Proportion of participants with an improvement of ≥4 points in Dermatology Life Quality Index (DLQI) score from Baseline to Week 24 and throughout the study

    The Dermatology Life Quality Index (DLQI) is a 10-item dermatology specific health-related quality of life (HRQoL) questionnaire. The total score is correlated to the detrimental effect of AD on QoL and ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: From Baseline throughout the study, up to Week 24

  19. Percent change in Dermatology Life Quality Index (DLQI) score from Baseline to Week 24 and throughout the study

    The Dermatology Life Quality Index (DLQI) is a 10-item dermatology specific health-related quality of life (HRQoL) questionnaire. The total score is correlated to the detrimental effect of AD on QoL and ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: From Baseline throughout the study, up to Week 24

  20. Percent change in Patient Oriented Eczema Measure (POEM) score from Baseline to Week 24

    The Scoring of Atopic Dermatitis (SCORAD) Index is a validated clinical tool that was developed to standardise the evaluation of the extent and severity of AD.

    Time frame: From Baseline throughout the study, up to Week 24,

  21. Percent change in Hospital Anxiety and Depression Scale (HADS) from Baseline to Week 24

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item patient-reported outcome (PRO) questionnaire used to assess states of anxiety and depression over the past week with two subscales. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: From Baseline throughout the study, up to to Week 24

  22. Incidence of Antidrug antibody (ADA) against lunsekimig up to end of study

    Time frame: From Baseline throughout the study, up to Week 32

  23. Serum concentrations of lunsekimig throughout the study

    Time frame: From Baseline throughout the study, up to Week 32

  24. Serum concentrations of lunsekimig in the pharmacokinetic/pharmacodynamics (PK/PD) subgroup throughout the study

    Time frame: From Baseline throughout the study, up to Week 32

  25. Number of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interest (AESIs), and serious adverse events (SAEs)

    Time frame: From Baseline throughout the study, up to Week 32

07

Study locations

52 sites
  • T. Joseph Raoof MD Inc-Site Number: 8400004
    Encino, California 91436, United States
  • Integrative Skin Science and Research-Site Number: 8400002
    Sacramento, California 95815, United States
  • Clinical Trials Research Institute-Site Number: 8400003
    Thousand Oaks, California 91320, United States
  • Skin Care Research-Site Number: 8400013
    Boca Raton, Florida 33486, United States
  • Driven Research LLC-Site Number: 8400020
    Coral Gables, Florida 33134, United States
  • Revival Research Institute, LLC-Site Number: 8400021
    Evans, Georgia 30809, United States
  • Treasure Valley Medical Research-Site Number: 8400026
    Boise, Idaho 83706, United States
  • Southern Indiana Clinical Trials-Site Number: 8400024
    New Albany, Indiana 47150, United States
  • Indiana Clinical Trials Center, P.C.-Site Number: 8400018
    Plainfield, Indiana 46168, United States
  • Optima Research-Site Number: 8400019
    Plainfield, Indiana 46168, United States
  • Options Research Group-Site Number: 8400012
    West Lafayette, Indiana 47906, United States
  • DS Research - Kentucky-Site Number: 8400005
    Louisville, Kentucky 40241, United States
  • Clinical Trials Management LLC-Site Number: 8400010
    Covington, Louisiana 70433, United States
  • Beacon Clinical Research-Site Number: 8400006
    Quincy, Massachusetts 02169, United States
  • Somerset Skin Centre-Site Number: 8400009
    Troy, Michigan 48084, United States
  • Medisearch LLC-Site Number: 8400017
    Saint Joseph, Missouri 64506, United States
  • Skin Cancer and Dermatology Institute-Site Number: 8400011
    Reno, Nevada 89509, United States
  • Icahn School of Medicine at Mount Sinai-Site Number: 8400023
    New York, New York 10029, United States
  • Red River Research Partners-Site Number: 8400008
    Fargo, North Dakota 58103, United States
  • Health Concepts-Site Number: 8400025
    Rapid City, South Dakota 57702, United States
  • DermResearch-Site Number: 8400014
    Austin, Texas 78759, United States
  • Progressive Clinical Research-Site Number: 8400001
    San Antonio, Texas 78213, United States
  • Burien US-WA 98168 Dermatology of Seattle and Bellevue-Site Number: 8400015
    Burien, Washington 98168, United States
  • Investigational Site Number: 0203003
    Prague, 101 00, Czechia
  • Investigational Site Number: 0203001
    Prague, 128 00, Czechia
  • Investigational Site Number: 0203004
    Prague, 128 00, Czechia
  • Investigational Site Number: 0203002
    Prague, 160 00, Czechia
  • Investigational Site Number: 3920005
    Asahikawa-shi, 070-8610, Japan
  • Investigational Site Number: 3920003
    Fukuoka, 812-8582, Japan
  • Investigational Site Number: 3920004
    Kofu, 400-8506, Japan
  • Investigational Site Number: 3920002
    Mibu, 321-0293, Japan
  • Investigational Site Number: 3920006
    Nerima-ku, 177-0041, Japan
  • Investigational Site Number: 3920001
    Ōta-ku, 160-0023, Japan
  • Investigational Site Number: 3920008
    Tachikawa-shi, 190-0023, Japan
  • Investigational Site Number: 3920007
    Yokohama, 221-0825, Japan
  • Investigational Site Number: 6160014
    Bochnia, 32-700, Poland
  • Investigational Site Number: 6160006
    Bydgoszcz, 85-231, Poland
  • Investigational Site Number: 6160010
    Jelenia Góra, 58-506, Poland
  • Investigational Site Number: 6160007
    Katowice, 40-611, Poland
  • Investigational Site Number: 6160003
    Katowice, 40-748, Poland
  • Investigational Site Number: 6160013
    Lublin, 20-011, Poland
  • Investigational Site Number: 6160001
    Mikołów, 43-190, Poland
  • Investigational Site Number: 6160011
    Nowa Sól, 67-100, Poland
  • Investigational Site Number: 6160015
    Ostrowiec Swietokrzyskie, 27-400, Poland
  • Investigational Site Number: 6160009
    Poznan, 60-192, Poland
  • Investigational Site Number: 6160012
    Sosnowiec, 41-200, Poland
  • Investigational Site Number: 6160004
    Szczecin, 70-332, Poland
  • Investigational Site Number: 6160017
    Warsaw, 01-142, Poland
  • Investigational Site Number: 6160018
    Warsaw, 02-172, Poland
  • Investigational Site Number: 6160002
    Warsaw, 02-953, Poland
  • Investigational Site Number: 6160005
    Wroclaw, 50-224, Poland
  • Investigational Site Number: 6160016
    Łodź, 91-495, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2026, 12 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 23, 2025
StartActual
Jan 30, 2025
Primary completionActual
Feb 12, 2026
CompletionActual
Apr 9, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06790121
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jan 30, 2025
Primary completion
Feb 12, 2026
Completion
Apr 9, 2026
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion